Nearly two years ago, we launched the industry's first solution combining early detection and tailored interventions to address the nation's costly health problem: medication nonadherence.
Leveraging predictive modeling, ScreenRx identifies patients with the highest risk for not taking medications as prescribed.
The tool considers more than 300 known factors about the patient, the physician, the disease and the prescribed therapy to identify who is most likely to stop taking their medication.
Once identified, patients receive personalized interventions to help them stay on their therapy.
The models are up to 94% accurate in predicting nonadherence one year in advance – nearly nine times more accurate than what patients self-report. ScreenRx shows an even greater adherence gap closure rate, 28.5% higher, when patients fill through home delivery over retail.
Increasing Healthcare Savings
In the first year of implementing this solution, ScreenRx contributed to nearly $30 million in total healthcare savings. We closed gaps in care for almost 125,000 patients.
Of patients targeted and impacted by ScreenRx, the solution added 9,869,536 incremental days of adherence.
Committed to Continuous Innovation
Last year, we were named one of Forbes’ Most Innovative Companies, largely due to smarter healthcare solutions like ScreenRx.
The tool has been awarded two patents for unique therapy adherence design and messaging to members.
While ScreenRx has made great strides in reframing the problem of adherence, Express Scripts is committed to continually innovating.
Better Patient Care
Express Scripts has recently updated the models to include depression and anticoagulants. We’ve also enhanced our Medicaid ScreenRx offering with models in five disease states including diabetes, hypertension, lipid disorders, depression, asthma and COPD.
These updates help more patients overcome nonadherence through tailored interventions.
comments powered by